^
    1year
    Poziotinib in Treatment-Naïve HER2 Exon 20 lung cancers: ZENITH20-Cohort 4 ORR 39%, DoR 7.6 mon, G778_P780dupGSP ORR 71%. @EGFRResisters @Exon20Group https://t.co/DvfkrlAD23 (@LeXiuning)
    EGFR exon 20 • HER2 exon 20
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation • HER-2 G778_P780dup • HER-2 exon 23 mutation
    |
    Pozenveo (poziotinib)
    1year
    Poziotinib in Treatment-Naïve HER2 Ex 20 Mutations: ZENITH20-4- Ph2 @JTOonline - N=80 - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash 45% stomatitis, diarrhea 15% - ⬆️ORR 71% in G778_P780dupGS ➡️ FDA declined 2nd line approval in 2022 pending more data #lcsm https://t.co/6CuMFdBTPk (@Latinamd)
    FDA event
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 G778_P780dup
    |
    Pozenveo (poziotinib)
    1year
    ZENITH20 Ph 2 Trial Poziotinib in HER2mt NSCLC @JTOonline: - 80pts - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash, stomatitis, diarrhea - G778_P780dupGSP HER2 mtn had ⬆️ORR 71% Early signal that mtn subtype matters in HER2mt NSCLC w pozi @OncoAlert #LCSM https://t.co/GXaoXlhOsb (@DrJNaidoo)
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 G778_P780dup
    |
    Pozenveo (poziotinib)
    1year
    Phase II study of 1L poziotinib in #HER2 NSCLC @JTOonline. In 80pts (47 at 16mg qd, 33 at 8mg bid), RR 39%, DCR 73%, mDOR 5.7m, mPFS 5.6m. G3+ AEs include rash (45% qd, 39% bid), mucositis (21%, 15%), diarrhea (15%, 21%). RR 71% in G778_P780dupGSP. https://t.co/hM5IF7UwHb (@StephenVLiu)
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 G778_P780dup
    |
    Pozenveo (poziotinib)